Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.79
NUVA's Cash to Debt is ranked lower than
55% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. NUVA: 0.79 )
Ranked among companies with meaningful Cash to Debt only.
NUVA' s 10-Year Cash to Debt Range
Min: 0.51   Max: No Debt
Current: 0.79

Equity to Asset 0.51
NUVA's Equity to Asset is ranked lower than
51% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 0.52 vs. NUVA: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
NUVA' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.93
Current: 0.51

0.36
0.93
Interest Coverage 0.65
NUVA's Interest Coverage is ranked higher than
58% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NUVA: 0.65 )
Ranked among companies with meaningful Interest Coverage only.
NUVA' s 10-Year Interest Coverage Range
Min: 0.65   Max: 9999.99
Current: 0.65

0.65
9999.99
F-Score: 7
Z-Score: 3.35
M-Score: -2.70
WACC vs ROIC
5.36%
7.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 13.00
NUVA's Operating margin (%) is ranked higher than
83% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -10.56 vs. NUVA: 13.00 )
Ranked among companies with meaningful Operating margin (%) only.
NUVA' s 10-Year Operating margin (%) Range
Min: -27436.54   Max: 6.71
Current: 13

-27436.54
6.71
Net-margin (%) 4.26
NUVA's Net-margin (%) is ranked higher than
68% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -12.96 vs. NUVA: 4.26 )
Ranked among companies with meaningful Net-margin (%) only.
NUVA' s 10-Year Net-margin (%) Range
Min: -27211.54   Max: 16.37
Current: 4.26

-27211.54
16.37
ROE (%) 5.28
NUVA's ROE (%) is ranked higher than
68% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: -14.48 vs. NUVA: 5.28 )
Ranked among companies with meaningful ROE (%) only.
NUVA' s 10-Year ROE (%) Range
Min: -322.04   Max: 21.43
Current: 5.28

-322.04
21.43
ROA (%) 2.59
NUVA's ROA (%) is ranked higher than
65% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -7.12 vs. NUVA: 2.59 )
Ranked among companies with meaningful ROA (%) only.
NUVA' s 10-Year ROA (%) Range
Min: -768.33   Max: 10.76
Current: 2.59

-768.33
10.76
ROC (Joel Greenblatt) (%) 33.17
NUVA's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -26.51 vs. NUVA: 33.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NUVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -737.95   Max: 17.53
Current: 33.17

-737.95
17.53
Revenue Growth (3Y)(%) 6.80
NUVA's Revenue Growth (3Y)(%) is ranked higher than
81% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NUVA: 6.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NUVA' s 10-Year Revenue Growth (3Y)(%) Range
Min: -40.2   Max: 486.2
Current: 6.8

-40.2
486.2
EPS Growth (3Y)(%) -40.70
NUVA's EPS Growth (3Y)(%) is ranked higher than
63% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NUVA: -40.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NUVA' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.3   Max: 31
Current: -40.7

-66.3
31
» NUVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

NUVA Guru Trades in Q2 2014

Paul Tudor Jones 13,082 sh (+48.66%)
Mario Gabelli 155,700 sh (+23.87%)
Vanguard Health Care Fund 1,628,303 sh (unchged)
Steven Cohen 437,000 sh (unchged)
Jim Simons 344,488 sh (-0.59%)
PRIMECAP Management 906,000 sh (-0.88%)
Ken Fisher 336,395 sh (-6.89%)
» More
Q3 2014

NUVA Guru Trades in Q3 2014

Louis Moore Bacon 130,000 sh (New)
Ken Fisher 1,177,679 sh (+250.09%)
Paul Tudor Jones 23,301 sh (+78.11%)
Steven Cohen 565,500 sh (+29.41%)
Mario Gabelli 166,700 sh (+7.06%)
Vanguard Health Care Fund 1,628,303 sh (unchged)
PRIMECAP Management 902,100 sh (-0.43%)
Jim Simons 126,288 sh (-63.34%)
» More
Q4 2014

NUVA Guru Trades in Q4 2014

Paul Tudor Jones 113,812 sh (+388.44%)
Ken Fisher 1,515,939 sh (+28.72%)
Jim Simons 142,488 sh (+12.83%)
Vanguard Health Care Fund 1,628,303 sh (unchged)
Mario Gabelli 166,700 sh (unchged)
Louis Moore Bacon Sold Out
PRIMECAP Management 901,800 sh (-0.03%)
Steven Cohen 272,000 sh (-51.90%)
» More
Q1 2015

NUVA Guru Trades in Q1 2015

Louis Moore Bacon 75,000 sh (New)
Jim Simons 396,588 sh (+178.33%)
Steven Cohen 437,800 sh (+60.96%)
Ken Fisher 1,554,352 sh (+2.53%)
Vanguard Health Care Fund 1,628,303 sh (unchged)
PRIMECAP Management 901,000 sh (-0.09%)
Mario Gabelli 161,200 sh (-3.30%)
Paul Tudor Jones 15,687 sh (-86.22%)
» More
» Details

Insider Trades

Latest Guru Trades with NUVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 77.40
NUVA's P/E(ttm) is ranked higher than
59% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NUVA: 77.40 )
Ranked among companies with meaningful P/E(ttm) only.
NUVA' s 10-Year P/E(ttm) Range
Min: 14.88   Max: 347.16
Current: 77.4

14.88
347.16
Forward P/E 36.76
NUVA's Forward P/E is ranked higher than
59% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NUVA: 36.76 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 75.40
NUVA's PE(NRI) is ranked higher than
67% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NUVA: 75.40 )
Ranked among companies with meaningful PE(NRI) only.
NUVA' s 10-Year PE(NRI) Range
Min: 14.85   Max: 332.29
Current: 75.4

14.85
332.29
P/B 3.90
NUVA's P/B is ranked lower than
57% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. NUVA: 3.90 )
Ranked among companies with meaningful P/B only.
NUVA' s 10-Year P/B Range
Min: 0.98   Max: 10.93
Current: 3.9

0.98
10.93
P/S 3.10
NUVA's P/S is ranked lower than
53% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NUVA: 3.10 )
Ranked among companies with meaningful P/S only.
NUVA' s 10-Year P/S Range
Min: 0.86   Max: 10.64
Current: 3.1

0.86
10.64
PFCF 130.60
NUVA's PFCF is ranked higher than
60% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NUVA: 130.60 )
Ranked among companies with meaningful PFCF only.
NUVA' s 10-Year PFCF Range
Min: 6.98   Max: 188.94
Current: 130.6

6.98
188.94
POCF 19.61
NUVA's POCF is ranked higher than
83% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NUVA: 19.61 )
Ranked among companies with meaningful POCF only.
NUVA' s 10-Year POCF Range
Min: 4.76   Max: 351.91
Current: 19.61

4.76
351.91
EV-to-EBIT 23.91
NUVA's EV-to-EBIT is ranked higher than
77% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NUVA: 23.91 )
Ranked among companies with meaningful EV-to-EBIT only.
NUVA' s 10-Year EV-to-EBIT Range
Min: -2590.2   Max: 484
Current: 23.91

-2590.2
484
Shiller P/E 635.90
NUVA's Shiller P/E is ranked higher than
62% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NUVA: 635.90 )
Ranked among companies with meaningful Shiller P/E only.
NUVA' s 10-Year Shiller P/E Range
Min: 519.38   Max: 635.9
Current: 635.9

519.38
635.9
Current Ratio 5.55
NUVA's Current Ratio is ranked higher than
82% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. NUVA: 5.55 )
Ranked among companies with meaningful Current Ratio only.
NUVA' s 10-Year Current Ratio Range
Min: 1.58   Max: 15.05
Current: 5.55

1.58
15.05
Quick Ratio 4.12
NUVA's Quick Ratio is ranked higher than
79% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. NUVA: 4.12 )
Ranked among companies with meaningful Quick Ratio only.
NUVA' s 10-Year Quick Ratio Range
Min: 1.14   Max: 13.9
Current: 4.12

1.14
13.9
Days Inventory 309.36
NUVA's Days Inventory is ranked lower than
61% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 198.08 vs. NUVA: 309.36 )
Ranked among companies with meaningful Days Inventory only.
NUVA' s 10-Year Days Inventory Range
Min: 84.66   Max: 491.78
Current: 309.36

84.66
491.78
Days Sales Outstanding 52.38
NUVA's Days Sales Outstanding is ranked higher than
82% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 96.55 vs. NUVA: 52.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
NUVA' s 10-Year Days Sales Outstanding Range
Min: 52.35   Max: 75.34
Current: 52.38

52.35
75.34

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.30
NUVA's Price/Tangible Book is ranked higher than
50% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. NUVA: 6.30 )
Ranked among companies with meaningful Price/Tangible Book only.
NUVA' s 10-Year Price/Tangible Book Range
Min: 2.36   Max: 34.31
Current: 6.3

2.36
34.31
Price/DCF (Projected) 2.80
NUVA's Price/DCF (Projected) is ranked higher than
77% of the 375 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NUVA: 2.80 )
Ranked among companies with meaningful Price/DCF (Projected) only.
NUVA' s 10-Year Price/DCF (Projected) Range
Min: 1.21   Max: 25.15
Current: 2.8

1.21
25.15
Price/Median PS Value 1.00
NUVA's Price/Median PS Value is ranked higher than
81% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NUVA: 1.00 )
Ranked among companies with meaningful Price/Median PS Value only.
NUVA' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 2.99
Current: 1

0.32
2.99
Price/Graham Number 4.70
NUVA's Price/Graham Number is ranked higher than
62% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NUVA: 4.70 )
Ranked among companies with meaningful Price/Graham Number only.
NUVA' s 10-Year Price/Graham Number Range
Min: 1.56   Max: 16.44
Current: 4.7

1.56
16.44
Earnings Yield (Greenblatt) 4.10
NUVA's Earnings Yield (Greenblatt) is ranked higher than
77% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: -2.60 vs. NUVA: 4.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
NUVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 4.8
Current: 4.1

0.2
4.8

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:NK8.Germany,
NuVasive Inc was incorporated in Delaware on July 21, 1997, and began commercializing its products in 2001. It is a medical device company engaged in developing minimally disruptive surgical products and procedures for the spine. The Company's current-marketed product portfolio is engaged in applications for spine fusion surgery, including biologics. The Company's product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS. The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide maximum visualization and are designed to enable safe and reproducible outcomes for the surgeon and the patient. The platform includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and Intra-Operative Monitoring (IOM) support; MaXcess, an integrated split-blade retractor system; and a variety of specialized implants. The Company's primary business model is to loan its MAS systems to surgeons and hospitals who purchase implants, biologics and disposables for use in individual procedures. In addition, for larger customers, the Company's proprietary nerve monitoring systems, MaXcess and surgical instrument sets are placed with hospitals for an extended period at no up-front cost to them. The Company also offers a range of bone allograft in patented saline packaging, disposables and spine implants, which include its branded CoRoent products and fixation devices such as rods, plates and screws. Implants, biologics and disposables are shipped from the Company's inventories. The Company sells an immaterial quantity of MAS instrument sets, MaXcess and nerve monitoring systems to hospitals. Its spine surgery product line offerings, which include products for the thoracolumbar and the cervical spine, are used to enable access to the spine and to perform restoration and fusion procedures in a minimally disruptive fashion. In the United States, it currently sells its products through a combination of exclusive independent sales agencies and directly-employed sales shareowners. The Company has 230 issued U.S. patents, 165 foreign national patents, and 284 pending patent applications. The Company's competitors are Medtronic Sofamor Danek (Medtronic), DePuy/Synthes, a Johnson & Johnson company, Stryker Spine, Globus Medical, Biomet Spine, and Zimmer Spine. It also faces competition from physician owned distributorships (PODs), which are medical device distributors that are owned, directly or indirectly, by physicians. The Company's products,medical devices and tissues subject to regulation by the FDA and other regulatory bodies.
» More Articles for NUVA

Headlines

Articles On GuruFocus.com
NuVasive(R) Demonstrates Expanding EMEA Business at Eurospine 2014 With Surgeon Workshops and Innova Oct 15 2014 
Guru Fisher Cuts NUVA - Medical Insurance Resists NuVasive Procedure Apr 11 2013 
NuVasive Inc. (NUVA) President and COO Keith Valentine sells 2,015 Shares Jan 25 2011 
Weekly Guru Bargains Highlights: ASIA , SAY , VRX , AMLN , NUVA Jan 09 2011 
Weekly Guru Bargains Highlights: ASIA, SAY, VRX, AMLN, NUVA Jan 01 2011 
Three Stocks for 2011: NUVA, ENOC, CBK Nov 25 2010 
NuVasive Inc. Reports Operating Results (10-Q) Nov 05 2010 
NuVasive Inc. Reports Operating Results (10-Q) Aug 06 2010 
NuVasive Inc. (NUVA) CEO and Chairman Alexis V Lukianov sells 5,000 Shares Jul 12 2010 
NuVasive Inc. (NUVA) President and COO Keith Valentine sells 5,000 Shares Jun 22 2010 

More From Other Websites
NuVasive to Participate in Investor Events in June 2015 May 28 2015
NuVasive to Participate in Investor Events in June 2015 May 28 2015
NuVasive Appoints Gregory T. Lucier Chief Executive Officer May 26 2015
8:32 am NuVasive appoints Gregory T. Lucier as CEO, effective immediately May 26 2015
NUVASIVE INC Files SEC form 8-K, Financial Statements and Exhibits May 26 2015
NuVasive Appoints Gregory T. Lucier Chief Executive Officer May 26 2015
Coverage initiated on NuVasive by Northland Capital May 14 2015
Is NuVasive (NUVA) Worth Adding to Your Portfolio Now? - Analyst Blog May 08 2015
CORRECTION - NuVasive(R) to Participate in Investor Events in May 2015 May 07 2015
NuVasive(R) to Participate in Investor Events in May 2015 May 07 2015
10-Q for NuVasive, Inc. May 06 2015
Correction: Earns-NuVasive story May 05 2015
Correction: Earns-NuVasive story May 05 2015
NuVasive Tops Q1 Earnings on High Revenues; Margins Rise - Analyst Blog May 05 2015
NuVasive attracts bullish strategy May 05 2015
NuVasive tops Street 1Q forecasts May 04 2015
NuVasive tops Street 1Q forecasts May 04 2015
NuVasive Inc Earnings Call scheduled for 4:30 pm ET today May 04 2015
NuVasive Reports First Quarter 2015 Financial Results May 04 2015
NUVASIVE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK